Osiris Therapeutics Announces Scientific Manuscript Reporting Antimicrobial Properties of Cryopreserved Viable Amnion is Avai...
January 13 2017 - 5:00PM
Osiris Therapeutics, Inc. (NASDAQ:OSIR), announced today that
a new peer-reviewed manuscript “Human cryopreserved viable
amniotic membrane inhibits the growth of bacteria associated with
chronic wounds” (Mao et al.) has been published in the Journal of
Diabetic Foot Complications and available online.
Chronic wounds are on the rise and represent an enormous
financial burden to the patient and to the healthcare system. Wound
related infection is a serious complication, which increases the
risk of hospitalization and often leads to amputation. Placental
membranes have a long history of use for management of wounds. One
of the properties of placental membranes in utero is to protect the
fetus from infections. However, limited availability and short
shelf-life precluded the widespread use of fresh placental tissues.
Progress in tissue preservation resulted in fast commercialization
of placental membranes. However, preservation techniques can lead
to varying degrees of damage to the tissue components, and
therefore affect the functional properties of placental
membranes.
In the published study, antimicrobial properties of human
cryopreserved viable amniotic membrane (hCVAM) were investigated.
This study was conducted in the laboratory of Professor Kohn at the
New Jersey Center for Biomaterials at Rutgers, The State University
of New Jersey. The effect of hCVAM against 6 pathogens associated
with chronic wounds – E. faecium, S. aureus, K. pneumoniae, A.
baumannii, P. aeruginosa, and E. aerogenes (ESKAPE) - was
evaluated. Results show that hCVAM inhibited the growth of all
ESKAPE bacteria in vitro.
“Deficiencies in chronic wound environment preclude wound
closure leading to high risk for wound infection. Therefore, wound
care modalities should not only support natural wound repair
process, but also possess antimicrobial properties. Results of the
study indicate that the cryopreserved viable placental amnion
retains both properties of the native tissue,” says Professor
Joachim Kohn, who is the Director of the New Jersey Center for
Biomaterials at Rutgers, The State University of New Jersey, the
Principal Investigator of the study.
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland, is a
world leader in researching, developing and marketing regenerative
medicine products that improve health and lives of patients and
lower overall healthcare costs. Having developed the world’s
first approved stem cell drug, the company continues to advance its
research and development in biotechnology by focusing on innovation
in regenerative medicine – including bioengineering, stem cell
research and viable tissue based products. Osiris has
achieved commercial success with products in orthopaedics, sports
medicine and wound care, including BIO4®, Cartiform®, Grafix®
and Stravix™.
Osiris, Grafix, Cartiform, and Stravix are trademarks of Osiris
Therapeutics, Inc. BIO4 is a trademark of Howmedica Osteonics
Corp. More information can be found on the company's website,
www.Osiris.com. (OSIR-G)
Forward-Looking Statements
This press release may contain forward-looking statements.
For a variety of reasons, actual results may differ materially from
those described in or contemplated by any such forward-looking
statement. Examples of forward-looking statements may
include, without limitation, forecast for commercial opportunities
or statements regarding anticipated efficiencies and advantages of
products or services. Consequently, the reader is cautioned
to consider all forward-looking statements in light of the risks to
which they are subject.
For additional information, please
contact:
Diane SavoieOsiris Therapeutics, Inc.(443)
545-1834 OsirisPR@Osiris.com
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Sep 2023 to Sep 2024